New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompareArgireline vs Survodutide

Argireline vs Survodutide

Side-by-side comparison of key properties, dosing, and research.

Skin & Cosmetic
Argireline
GLP-1 / Weight Loss Agonists
Survodutide
Summary
Argireline is the most widely researched topical 'Botox-alternative' cosmetic peptide, an acetylated hexapeptide that inhibits neuromuscular transmission to relax facial muscles and reduce dynamic wrinkle depth by 17–27% in clinical studies.
Survodutide is a once-weekly GLP-1/glucagon dual receptor agonist developed by Boehringer Ingelheim and Zealand Pharma. Phase 2 trials demonstrated up to 18.7% body weight reduction at 46 weeks, among the highest reported for a dual agonist. It is being studied for obesity and MASH (metabolic dysfunction-associated steatohepatitis), where the glucagon component drives hepatic fat clearance.
Half-Life
N/A — topical application; effect duration linked to formulation contact time
~7 days
Admin Route
Topical
SubQ
Research
Typical Dose
5–10% concentration
0.6 mg → 2.4 mg → 4.8 mg → 6 mg
Frequency
Twice daily
Once weekly
Key Benefits
  • Reduces depth of dynamic expression wrinkles 17–27%
  • Non-invasive topical Botox alternative
  • Smooths forehead, eye area, nasolabial fold lines
  • Widely studied — published clinical efficacy data
  • Synergistic with SNAP-8 for enhanced effect
  • Reduces fine lines around eyes (crow's feet)
  • Improves skin smoothness and texture
  • Well tolerated across all skin types
  • Up to 18.7% body weight reduction at 46 weeks (Phase 2)
  • Strong MASH activity — Phase 3 SYNCHRONIZE-NASH trials ongoing
  • Reduces hepatic fat content via glucagon receptor-driven liver oxidation
  • Once-weekly subcutaneous injection
  • Greater weight loss potential than GLP-1 monotherapy
  • Improvements in liver fibrosis markers in early data
Side Effects
  • Generally very well tolerated
  • At >10%: temporary eyelid/brow ptosis (drooping)
  • Rare: mild redness in sensitive skin
  • No systemic absorption at cosmetic doses
  • Nausea (most common during titration)
  • Vomiting
  • Diarrhea
  • Decreased appetite
  • +3 more
Stacks With